Inhibiting HMGCR or squalene synthase (the enzyme in the first step of cholesterol biosynthesis) to deplete cholesterol can enhance the sensitivity of HCC cells to chemotherapy (107, 163, 164). Here, FDFT1 is linked to hepatocellular carcinoma.